How Boston Scientific Makes Money

Boston Scientific operates a high-margin, resilient medical device business model built on single-use consumable catheters, implantable structural devices, and specialized capital equipment: (1) Cardiovascular (~62% of revenue / ~$8.8B), generating robust sales from coronary stents (Synergy), intravascular ultrasound (OptiCross), WATCHMAN left atrial appendage closure devices, and peripheral vascular atherectomy tools; (2) MedSurg (~29% of revenue / ~$4.1B), monetizing disposable endoscopes (Single-Use EXALT), stone management lithotripsy lasers, and urology implants; (3) Neuromodulation (~9% of revenue / ~$1.3B), delivering implantable neurostimulators (WaveWriter Alpha) and deep brain stimulation consoles; and (4) Capital-and-Consumable Placement: Consoles (such as FARASTAR pulsed field ablation generators and POLARx cryoablation consoles) are placed in hospital catheterization labs, locking electrophysiologists into continuous, recurring daily utilization of high-margin single-use catheters. Boston Scientific maintains gross margins above 70% and generates over $2.1 billion in annual free cash flow.

Under CEO Michael Mahoney, Boston Scientific is executing a clear four-pronged growth strategy: (1) Scaling Global FARAPULSE Adoption: Expanding manufacturing capacity and commercial distribution across North America, Europe, and Asia-Pacific to convert conventional thermal cardiac ablations to pulsed field ablation; (2) Expanding WATCHMAN Indications: Advancing the CHAMPION-AF clinical trial to expand WATCHMAN label indications as a first-line alternative to direct oral anticoagulants (DOACs); (3) Accelerating Endoscopy Single-Use Transition: Commercializing single-use duodenoscopes and bronchoscopes (EXALT platform) to eliminate the risk of hospital patient cross-contamination associated with reprocessed reusable endoscopes; and (4) Expanding Neuromodulation & Pelvic Health via Axonics: Integrating the $3.7B acquisition of Axonics to capture the multi-billion-dollar sacral neuromodulation market for urinary and bowel dysfunction.